Cite
HARVARD Citation
Laloi, L. et al. (2023). Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Cancer medicine. pp. 7175-7181. [Online].